Eli Lilly’s Mounjaro, Zepbound Back in Stock After Extended Shortage, FDA Says

Months of an ongoing supply squeeze for Eli Lilly’s tirzepatide-based meds have lifted, according to the FDA.

After placing nearly all doses of the company’s diabetes drug Mounjaro and its obesity counterpart Zepbound on the agency’s shortage list in April, all doses of the meds are now listed as available. Mounjaro’s first appearance on the list was all the way back in 2022.

The shortage, which has been attributed to fervent demand outweighing supply, has caused the company to pour billions into extra supply capacity. By the end of the first quarter, seven sites expected to help ease the supply woes were either “ramping up or under construction,” chief financial officer Anat Ashkenazi said on a previous earnings call.

Read more at Fierce Pharma >>